# Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

> **NCT06961331** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 86 (actual)

## Conditions studied

- Metastatic HER2+ Advanced Breast Cancer

## Interventions

- **DRUG:** Tucatinib
- **DRUG:** Trastuzumab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06961331
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-05-07
- **Primary completion:** 2025-09-25
- **Final completion:** 2025-09-25
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06961331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06961331, "Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06961331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*